News FDA starts kicks off review of Gilead's weekly HIV pill The FDA is due to deliver a verdict in February on Gilead's once-weekly pill for HIV PrEP, which could expand the options available to patients.
News MSD's Sac-TMT delivers in first phase 3 readout MSD's TROP2-targeting antibody-drug conjugate sac-TMT, licensed from China's Kelun, has improved survival in a late-stage endometrial cancer trial.
News NICE backs stomach cancer, PAH drugs for NHS use AZ's Imfinzi is the first NHS immunotherapy for a form of stomach cancer, while MSD's Winrevair gets a green light for rare respiratory disease PAH.
News MSD cuts $1bn AI tool deal with Google Cloud MSD has agreed a deal with Google Cloud that will put the tech giant's AI tools in the hands of its 75,000 employees worldwide.
News MSD, Eisai report setback in first-line kidney cancer trial The LITESPARK-012 trial saw no benefit when Welireg was added to treatment with Keytruda plus Lenvima for renal cell carcinoma.
News Update: Rumour confirmed as MSD buys Terns for $6.7bn MSD's glut of pipeline-boosting deals in the build-up to a looming patent cliff has continued with a $6.7bn bid to acquire Terns Pharma.
News Isomorphic Labs raises $5bn in massive third round In yet another sign of the appetite for AI companies among investors, Isomorphic Labs has raised a whopping $5bn in a Series C financing.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.